Biotech Startups

Tetra Pharm develops next-generation drugs targeting neurological disorders including chronic pain, Alzheimer's, and obesity. The company also provides contract development and manufacturing organization (CDMO) services encompassing drug delivery systems, GMP manufacturing, and consultancy to pharmaceutical clients.

1 investor

Tetratherix develops a biostealth fluid matrix built on its Tetramatrix platform technology to create regenerative medicine therapies, solutions, and products. The company operates in the regenerative medicine and medical device field and runs its own advanced manufacturing facility.

1 investor

1 investor

Tezcat develops protein-drug conjugates that use the macropinocytosis process to deliver toxic payloads selectively to cancer cells, with a focus on RAS-activated and other aggressive cancers. Its receptor-independent delivery platform is designed to be disease- and payload-agnostic, supporting applications across oncology, neurodegenerative, inflammatory, and infectious diseases.

1 investor

A biotech company developing novel biologics designed to target and eliminate the drivers of cancer recurrence and metastasis. It combines early-stage research with platform design to create treatments for resilient cancers.

1 investor

Trinity Life Sciences provides commercialization intelligence for the life sciences industry, combining expert consulting with AI-based data and analytics to support drug launch and market decisions. It serves pharmaceutical and life sciences companies with services and software for forecasting revenue outcomes and navigating go-to-market strategy.

1 investor

Thabor Therapeutics is an INSERM spin-off developing a first-in-class therapeutic antibody targeting AGR2 for treating inflammatory mucosal diseases. The company focuses on immunology and therapeutic antibody development.

1 investor

1 investor

Tharos is a British company that develops enzyme-based nutritional technologies and digestive-health products for horses and dogs, translating microbiome and digestion research into specialist animal-health brands. It serves equine and canine markets across Britain, Europe and the United States through dedicated brands and fulfilment routes.

1 investor

The Blue Box is a diagnostic device that uses a urine reader with an electronic nose and AI analysis to detect breast cancer biomarkers in women aged 20-49 who lack reliable screening methods. The company has validated its technology through pilots with over 450 patients across 7 hospitals.

1 investor

The Century of Biology is a newsletter publishing analysis, data, and commentary about companies and ideas in the field of biology. It is written by Elliot Hershberg and distributed on Substack to over 28,000 subscribers.

1 investor

The Pennycress Company develops pennycress oil as a renewable fuel feedstock for biodiesel, renewable diesel, and sustainable aviation fuel production. Grown as a winter annual on fallow farmland, the feedstock avoids crop displacement while reducing lifecycle greenhouse gas emissions and qualifies for government low-carbon fuel incentive programs.

1 investor

Ritedose is a contract development and manufacturing organization (CDMO) that produces generic and specialty medications using advanced data analysis and custom technology solutions. The company serves patients and pharmaceutical clients by manufacturing high-quality drugs in cGMP-compliant facilities while maintaining a focus on safety, quality, and environmental sustainability.

1 investor

The Siesta Group provides computer-assisted sleep scoring and EEG biomarker extraction services, with AI-powered analysis of biometric signals for pharmaceutical and biotechnology firms. The company supports clinical trials focused on neurology therapies through centralized scoring and proprietary biomarker research tools.

1 investor

The Data Guild is a venture studio that builds companies addressing challenges in healthcare, life sciences, renewable energy, and climate change. It operates with a model of hiring "members" rather than traditional staff, drawing on an expert network to develop portfolio companies.

1 investor

TheiaNova is developing a non-surgical therapy to induce remodeling of the cornea for patients with ectatic vision disorders such as keratoconus. The company, spun out of research at the University of Auckland's Department of Ophthalmology, is a biotech working to bring this corneal therapeutic agent to the clinic.

1 investor

MRN operates a decentralized clinical trial site network that connects trial sponsors with diverse patient populations through flexible, community-based delivery models. The platform provides participating sites with eClinical technology, staffing support, and project management to enable faster patient recruitment and retention across traditional, hybrid, and remote trial settings.

1 investor

A venture capital or advisory firm with partners across Europe, the US, and Asia who provide mentorship and investment guidance to startups in cloud, AI, and deeptech sectors.

1 investor

Theodorus is a venture capital firm that finances seed and early-stage life sciences and high-tech companies, managing over €38M across four funds. It presents itself to limited partners as one of the top-performing university spin-off funds in Europe.

1 investor

Theora partners with Indian healthcare organizations to aggregate, structure, and de-identify clinical and genomic data for pharmaceutical and AI research, addressing the underrepresentation of Indian populations in drug discovery and genetic studies.

1 investor

TheraCryf is developing Ox-1, a candidate-stage orexin-1 receptor antagonist molecule intended to treat substance use disorders (addictive behaviours) and anxiety. The compound is at late pre-clinical stage and funded toward regulatory submissions for Phase 1 human volunteer studies.

1 investor

Theragene Pharmaceuticals develops immunotherapy and gene therapy treatments for cancer and cardiovascular diseases using AAV technology. The company operates in the US and Asia, pursuing partnerships for product development and licensing.

1 investor

Therakos develops THERAKOS Photopheresis, an FDA-approved extracorporeal photopheresis (ECP) system used to treat skin symptoms of cutaneous T-cell lymphoma (CTCL) unresponsive to other treatments. It provides medical devices and associated drug therapy for clinicians treating CTCL patients.

1 investor

1 investor